Australia markets close in 5 hours 16 minutes

Jounce Therapeutics, Inc. (JNCE)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
8.55-0.37 (-4.15%)
At close: 4:00PM EDT
8.54 -0.01 (-0.12%)
After hours: 04:55PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close8.92
Open8.95
Bid8.03 x 1000
Ask8.95 x 1200
Day's range8.53 - 9.03
52-week range5.03 - 14.84
Volume253,559
Avg. volume409,115
Market cap438.034M
Beta (5Y monthly)0.98
PE ratio (TTM)N/A
EPS (TTM)-0.47
Earnings date04 Nov 2021 - 08 Nov 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est14.50
  • GlobeNewswire

    Jounce Therapeutics Progresses INNATE Study of JTX-8064 (LILRB2/ILT4 Inhibitor) Monotherapy and Pimivalimab (PD-1 Inhibitor) Combination Therapy in Patients with Advanced Solid Tumors

    - Enrollment initiated in tumor-specific monotherapy and pimivalimab combination expansion cohorts – - Monotherapy and pimivalimab combination dose escalation enrollment completed - CAMBRIDGE, Mass., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced the initiation of patient enrollment in INNATE tumor-specific expansion cohorts for

  • GlobeNewswire

    Jounce Therapeutics Appoints Jigar Raythatha to its Board of Directors

    CAMBRIDGE, Mass., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (Nasdaq: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced the appointment of former chief executive officer of Constellation Pharmaceuticals and former Jounce chief business officer, Jigar Raythatha, to its board of directors. β€œIt’s incredibly exciting to welcome Jigar to our board of directors. Not only does Jigar bring

  • GlobeNewswire

    Jounce Therapeutics to Present at Upcoming Investor Conferences in September

    CAMBRIDGE, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that company management will participate at several upcoming investor conferences in September: 2021 Wells Fargo Virtual Healthcare Conference: Fireside chat on Friday September 10, 2021 at 8:00 a.m. ET.H.C. Wainwright 23rd Annual Global Investment Conference: Pre